Spinifex Pharmaceuticals Report issue

For profit Phase 2
Founded: Preston United Kingdom (2005)
Status: Acquired by Novartis (2015)

Organization Overview

First Clinical Trial
2015
NCT02426411
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Spinifex Pharmaceuticals Pty Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

ema400 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1